The Parkinson's Progression Markers Initiative (PPMI) is a comprehensive clinical study launched in 2010 to identify biomarkers of [Parkinson's Disease](/diseases/parkinsons-disease) progression.[@marek2023] The study enrolls both individuals with Parkinson's Disease and healthy controls to identify objective markers that can track disease [@marek2023] progression.[@parkinson2014]
Study Design
PPMI employs a multi-arm observational design with three main cohorts: [@postuma2015]
...
Introduction
Overview
Mermaid diagram (expand to render)
The Parkinson's Progression Markers Initiative (PPMI) is a comprehensive clinical study launched in 2010 to identify biomarkers of [Parkinson's Disease](/diseases/parkinsons-disease) progression.[@marek2023] The study enrolls both individuals with Parkinson's Disease and healthy controls to identify objective markers that can track disease [@marek2023] progression.[@parkinson2014]
Study Design
PPMI employs a multi-arm observational design with three main cohorts: [@postuma2015]
PPMI has been instrumental in demonstrating that [alpha-synuclein](/proteins/alpha-synuclein) seeding activity in CSF can distinguish PD from healthy controls with high sensitivity and specificity.[@singer2022] [@berg2014]
Neurofilament Light Chain
Elevated [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in CSF and blood correlates with more rapid disease progression in PD.[@bacioglu2016] [@iranzo2013]
Genetic Risk Factors
PPMI has identified that [GBA](/entities/gba) mutations and [LRRK2](/entities/lrrk2) variants influence disease progression and clinical phenotypes.[@liu2019] [@espay2020]
At-Risk Cohorts
Individuals with RBD have a high likelihood of developing synucleinopathies, with conversion rates of 80-90% over 10-15 years.[@postuma2019] [@fereshtehnejad2019]
Impact on Clinical Trials
PPMI data have enabled: [@kalia2015]
Better patient selection for clinical trials[@cedarbaum2018]
Identification of progression biomarkers for outcome measures[@hauser2020]
Understanding of disease heterogeneity[@titova2017]
Enrichment strategies for faster trials[@evans2016]
Participating Institutions
PPMI involves over 50 clinical sites worldwide, including major research universities in North America, Europe, and Asia. [@lang2019]
Data Access
All PPMI data are freely available to qualified researchers through the PPMI website, enabling global research collaboration.[@ppmi2024] [@goetz2010]
The study of Parkinson'S Progression Markers Initiative (Ppmi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@doty1984]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@stiasnykolster2007]